DGIdb - FORMESTANE Drug Record

FORMESTANE chembl:CHEMBL132530 Approved

Alternate Names:

CGP-32349
LENTARON
FORMESTANE
4-HYDROXYANDROSTENEDIONE
FORMESTANO
4-HYDROXY-DELTA(4)-ANDROSTENEDIONE
FORMESTANUM
CGP 32349
4-OH-A
LTR323
4-OHAD
4-HYDROXY-Δ4-ANDROSTENEDIONE
4-HYDROXY-4-ANDROSTENE-3,17-DIONE
drugbank:08905
rxcui:15070
pubchem.compound:11273
chemidplus:566-48-3
chembl:CHEMBL132530

Drug Info:

(0 More Sources)

Publications:

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
Coombes et al., 1984, 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer., Lancet

FORMESTANE CYP1B1

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18256205

Sources:
NCI
FORMESTANE CYP19A1

Interaction Score: 0.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6150277

Sources:
NCI
FORMESTANE TARDBP

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FORMESTANE AR

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

NCI: FORMESTANE
- Version: 14-September-2017
Alternate Names:

C974 NCI drug code

Drug Info:

Publications:

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
NCI: 4-HYDROXYANDROSTENEDIONE
- Version: 14-September-2017
Alternate Names:

C974 NCI drug code

Drug Info:

Publications:

Coombes et al., 1984, 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer., Lancet
DTC: FORMESTANE
- Version: 02-September-2020
Alternate Names:

CHEMBL132530 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL132530
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

FORMESTANE Drug Record

FORMESTANE chembl:CHEMBL132530 Approved

Alternate Names:

Drug Info:

Publications:

FORMESTANE CYP1B1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18256205

Sources: NCI

FORMESTANE CYP19A1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6150277

Sources: NCI

FORMESTANE TARDBP

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

FORMESTANE AR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

NCI: FORMESTANE

Alternate Names: C974 NCI drug code

Drug Info:

Publications: Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.

NCI: 4-HYDROXYANDROSTENEDIONE

Alternate Names: C974 NCI drug code

Drug Info:

Publications: Coombes et al., 1984, 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer., Lancet

DTC: FORMESTANE

Alternate Names: CHEMBL132530 ChEMBL Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL132530

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
18256205

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6150277

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

C974 NCI drug code

Publications:

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.

Alternate Names:

C974 NCI drug code

Publications:

Coombes et al., 1984, 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer., Lancet

Alternate Names:

CHEMBL132530 ChEMBL Drug ID